Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 64%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is a leader in the oncology-focused biopharmaceutical market due to its diverse portfolio and strong financial standing. With the success of their top BTK inhibitor, Brukinsa, and promising treatments for solid tumors in their pipeline, the company is well positioned for continued growth. Experts view Brukinsa as a top choice for treating CLL, and with a projected peak sales of $7.1B, BeOne Medicines has the potential to deliver strong returns for investors. As the company remains committed to innovation and sustainability, it presents a promising investment opportunity with a Buy recommendation and $400 price target.

Bears say

BeOne Medicines is currently an oncology-focused biopharmaceutical company, but faces significant challenges in maintaining its current position and driving future growth. With Brukinsa being its primary revenue driver, any decline in sales or setbacks in pipeline programs could have a significant impact on the company's financials. Additionally, the company's reliance on the success of early-stage assets like sonrotoclax and BTK CDAC pose a risk, as delays or failures could hinder their future commercialization. There is also the risk of competition increasing, particularly for Brukinsa, from other companies in the crowded heme-onc space. Lastly, the company faces a potential geopolitical risk due to its Chinese roots, which could negatively impact investor sentiment.

BeiGene Ltd (ONC) has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 64% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 11 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $386.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $386.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.